Chenguang Yang

Dec 18, 2024 | peerj.com | Chenguang Yang

As global environmental concerns grow, the focus on energy efficiency in various sectors, including manufacturing and logistics, has become increasingly important. In warehouse environments, where space is often constrained and the presence of other mobile robots and densely packed shelves create complex and dynamic navigation challenges, the need for energy-efficient autonomous mobile robots (AMRs) is critical.

Nov 28, 2024 | onlinelibrary.wiley.com | Zongyu Liu |Hongyu Chu |Weidong Zhao |Chenguang Yang

1 Introduction Opdivo (nivolumab) plus Yervoy (ipilimumab) is dual immunotherapy targeting and blocking the immune checkpoints PD1 and CTLA-4, and has been successfully applied in clinical cancer therapy,[1] including colorectal cancer,[2] hepatocellular carcinoma,[3] and non-small cell carcinoma.[4] Less than 30% of cancer patients respond to immune checkpoint therapy, but treatment with Opdivo plus Yervoy at an optimum dosage ratio of 3:1 enhances antitumor efficacy.

Oct 31, 2024 | arxiv.org | James Knowles |Chenguang Yang |Cunjia Liu |Yunda Yan

Mar 19, 2024 | nature.com | Chenguang Yang |Ming Li |Yong Huei Wang |Lu Ma

AbstractHomotypic membrane fusion of the endoplasmic reticulum (ER) is mediated by dynamin-like GTPase atlastin (ATL). This fundamental process relies on GTP-dependent domain rearrangements in the N-terminal region of ATL (ATLcyto), including the GTPase domain and three-helix bundle (3HB). However, its conformational dynamics during the GTPase cycle remain elusive. Here, we combine single-molecule FRET imaging and molecular dynamics simulations to address this conundrum.